form8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
————————————
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 30, 2013 (April 29, 2013)
————————————
PRAXAIR, INC.
(Exact name of registrant as specified in its charter)
————————————
|
Delaware
|
1-11037
|
06-1249050
|
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission file number)
|
(I.R.S. Employer
Identification No.)
|
39 Old Ridgebury Road
Danbury, CT 06810-5113
(Address of principal executive offices)
(203) 837-2000
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
————————————
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
On April 29, 2013, Praxair, Inc. (the “Company”) priced $475,000,000 aggregate principal amount of 1.250% notes due November 7, 2018 (the “2018 Notes”) and $175,000,000 aggregate principal amount of 3.550% notes due November 7, 2042 (the “2042 Notes” and, together with the 2018 Notes, the “Notes”). The 2042 Notes will be of the same series as the $300,000,000 of 3.550% Notes due 2042 that the Company issued on November 7, 2012. The Notes will be sold on May 7, 2013 in a registered offering under the Securities Act of 1933, pursuant to the Company’s shelf registration statement on Form S-3 filed with the Securities and Exchange Commission (“SEC”) on August 8, 2012. The material terms of the Notes are described in the Company’s prospectus supplement dated April 29, 2013 filed with the SEC on April 30, 2013.
In connection with the pricing of the Notes, the Company entered into a Terms Agreement dated April 29, 2013 (the “Terms Agreement”) with Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC and RBS Securities Inc., as representatives of the underwriters named therein (the “Underwriters”). Pursuant to and subject to the terms and conditions of the Terms Agreement, the Underwriters agreed to purchase the Notes from the Company for resale in the registered offering. The Terms Agreement is filed as Exhibit 1 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed herewith:
|
Exhibit No.
|
Description
|
|
1
|
Terms Agreement dated April 29, 2013
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 30, 2013
|
PRAXAIR, INC.
By: /s/ James T. Breedlove
James T. Breedlove
Senior Vice President,
General Counsel and Secretary
|
Exhibit Index
|
Exhibit No.
|
Description
|
|
1
|
Terms Agreement dated April 29, 2013
|